Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash

Executive Summary

Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.

Advertisement

Related Content

Argenx Nears Phase III In Myasthenia Gravis
Interview: GW Pharma Gears Up For Pivotal 2018
Celgene's CAR-T Leadership Goals Advance At ASH 2017
resTORbio's Age-Related RTI Program Picks Up Further Funding
While The Money Flows, So Will Biopharma IPOs
Valeant Sees Sunshine On Cloudy Day, But Dermatology Recovery Just Starting
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
Neuroscience Reaches A New Inflection Point, Big Biotechs Say
Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel